中国老年高血压管理指南2019
|
摘要
<正>前言人口老龄化已经成为重大的社会问题,至2017年末,我国年龄≥65岁人口1亿5831万人,占总人口的11.4%。为了积极应对人口变化带来的挑战,我国卫生行业遵循"健康老龄化"的原则,从"以疾病治疗为中心",转变为"以人民健康为中心",坚决贯彻"预防为主"的理念,进一步推进卫生和健康事业的发展。高血压是最常见的慢性病之一。半数以上的老年人患有高血压,而在年龄≥80岁的高龄人群中,高血压的患病率接近90%,是罹患脑卒中、心肌梗死
引文
[1] World Health Organization, International Society of Hypertension writing group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension[J].J Hypertens,2003,21(11):1983-1992.
[2] 王薇,赵冬. 中国老年人高血压的流行病学[J].中华老年医学杂志,2005,24(4):246-247.
[3] 李立明,饶克勤,孔灵芝,等. 中国居民2002年营养与健康状况调查[J].中华流行病学杂志,2005,26(7):478-484.
[4] 李苏宁,陈祚,王增武,等. 我国老年人高血压现状分析[J].中华高血压杂志,2019,27(2):140-148.
[5] Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002[J].Circulation,2008,118(25):2679-2686.
[6] 范国辉,王增武,张林峰,等. 2013年北方四区县农村高血压患病率,知晓率,治疗率和控制率调查[J].中华医学杂志,2015,95(8):616-620.
[7] Yang L, Yan J, Tang X, et al. Prevalence, awareness, treatment, control and risk factors associated with hypertension among adults in Southern China, 2013[J].PLoS One,2016,11(1):e0146181.
[8] Gu H, Li W, Yang J, et al. Hypertension prevalence, awareness, treatment and control among Han and four ethnic minorities (Uygur, Hui, Mongolian and Dai) in China[J].J Hum Hypertens,2015,29(9):555-560.
[9] 王志军,柯元南,周建芝. 老年高血压患者的血压控制现状及影响因素分析[J].中华老年心脑血管病杂志,2008,10(4):246-249.
[10] Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly:a report of the American College of Cardiology foundation task force on clinical expert consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension[J].J Am Soc Hypertens,2011,5(4):259-352.
[11] 吴锡桂,段秀芳,黄广勇,等. 我国老年人群单纯性收缩期高血压患病率及影响因素[J].中华心血管病杂志,2003,31(6):456-459.
[12] 中国老年医学学会高血压分会. 高龄老年人血压管理中国专家共识[J].中华高血压杂志,2015,23(12):1127-1134.
[13] Franklin SS, Wilkinson IB, McEniery CM. Unusual hypertensive phenotypes:what is their significance?[J].Hypertension,2012,59(2):173-178.
[14] Sheng CS, Liu M, Zeng WF, et al. Four-limb blood pressure as predictors of mortality in elderly Chinese[J].Hypertension,2013,61(6):1155-1160.
[15] Stergiou GS, Siontis KC, Ioannidis JP. Home blood pressure as a cardiovascular outcome predictor:it's time to take this method seriously[J].Hypertension,2010,55(6):1301-1303.
[16] Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home:a summary report of the second international consensus conference on home blood pressure monitoring[J].J Hypertens,2008,26(8):1505-1526.
[17] 中国医师协会高血压专业委员会,中国高血压联盟,中华医学会心血管病学分会.家庭血压监测中国专家共识[J].中华高血压杂志,2012,20(6):525-529.
[18] 中国高血压联盟,中国医师协会高血压专业委员会血压测量与监测工作委员会,《中华高血压杂志》编委会.动态血压监测临床应用中国专家共识[J].中华高血压杂志,2015,23(8):727-730.
[19] Parati G, Stergiou G, O'Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring[J].J Hypertens,2014,32(7):1359-1366.
[20] Li Y, Staessen JA, Lu L, et al. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study[J].Hypertension,2007,50(2):333-339.
[21] 中国老年医学学会高血压分会. 老年人异常血压波动临床诊疗中国专家共识[J].中华高血压杂志,2017,25(2):132-139.
[22] 华琦,朱玉仑. 超声心动图检测年龄进程中心功能的衍变特点[J].中华心血管病杂志,1990,18(4):212-214.
[23] 中国高血压防治指南修订委员会. 中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-743.
[24] 赵冬,吴兆苏,王薇,等. 中国11省市队列人群基线血压和7年累积心血管病发病危险的前瞻性研究[J].中华心血管病杂志,2001,29(10):612-617.
[25] Gu D, Gupta A, Muntner P, et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China:results from the international collaborative study of cardiovascular disease in Asia (InterAsia)[J].Circulation,2005,112(5):658-665.
[26] 刘军,王薇,刘静,等. 门诊高血压病患者合并心血管病危险因素及血压控制现况[J].中华心血管病杂志,2013,41(12):1050-1054.
[27] Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical paradigm-issues and controversies[J].J Gerontol A Biol Sci Med Sci,2007,62(7):731-737.
[28] Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults[J].J Am Coll Cardiol,2014,63(8):747-762.
[29] 李建华,范利,赵婷,等.老年高血压患者发生衰弱对预后的影响[J].中华老年多器官疾病杂志,2018,17(5):324-328.
[30] Odden MC, Covinsky KE, Neuhaus JM, et al. The association of blood pressure and mortality differs by self-reported walking speed in older Latinos[J].J Gerontol A Biol Sci Med Sci,2012,67(9):977-983.
[31] Odden MC, Peralta CA, Haan MN, et al. Rethinking the association of high blood pressure with mortality in elderly adults:the impact of frailty[J].Arch Intern Med,2012,172(15):1162-1168.
[32] Peralta CA, Katz R, Newman AB, et al. Systolic and diastolic blood pressure, incident cardiovascular events, and death in elderly persons:the role of functional limitation in the cardiovascular health study[J].Hypertension,2014,64(3):472-480.
[33] Post Hospers G, Smulders YM, Maier AB, et al. Relation between blood pressure and mortality risk in an older population:role of chronological and biological age[J].J Intern Med,2015,277(4):488-497.
[34] Ravindrarajah R, Hazra NC, Hamada S, et al. Systolic blood pressure trajectory, frailty, and all-cause mortality >80 years of age:cohort study using electronic health records[J].Circulation,2017,135(24):2357-2368.
[35] Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG):a double-blind, placebo controlled trial[J].Lancet Neurol,2008,7(8):683-689.
[36] Pajewski NM, Williamson JD, Applegate WB, et al. Characterizing frailty status in the systolic blood pressure intervention trial[J].J Gerontol A Biol Sci Med Sci,2016,71(5):649-655.
[37] Williamson JD, Supiano MA, Pajewski NM. Intensive vs standard blood pressure control for older adults-reply[J].JAMA,2016,316(18):1923.
[38] Benetos A, Bulpitt CJ, Petrovic M, et al. An Expert opinion from the European Society of Hypertension-European Union Geriatric Medicine Society working group on the management of hypertension in very old, frail subjects[J].Hypertension,2016,67(5):820-825.
[39] Morley JE, Vellas B, van Kan GA, et al. Frailty consensus:a call to action[J].J Am Med Dir Assoc,2013,14(6):392-397.
[40] Bursztyn M. Hypertension, its treatment, frailty, falls, and mortality[J].Hypertension,2017,70(2):253-254.
[41] 中华医学会老年医学分会.老年患者衰弱评估与干预中国专家共识[J].中华老年医学杂志,2017,36(3):251-256.
[42] Bromfield SG, Ngameni CA, Colantonio LD, et al. Blood pressure, antihypertensive polypharmacy, frailty, and risk for serious fall injuries among older treated adults with hypertension[J].Hypertension,2017,70(2):259-266.
[43] Kojima G. Frailty defined by FRAIL scale as a predictor of mortality:a systematic review and meta-analysis[J].J Am Med Dir Assoc,2018,19(6):480-483.
[44] Yano Y, Inokuchi T, Kario K. Walking speed is a useful marker of frailty in older persons[J].JAMA Intern Med,2013,173(4):325-326.
[45] Fried LP, Tangen CM, Walston J, et al. Frailty in older adults:evidence for a phenotype[J].J Gerontol A Biol Sci Med Sci,2001,56(3):M146-156.
[46] Dent E, Lien C, Lim WS, et al. The Asia-Pacific clinical practice guidelines for the management of frailty[J].J Am Med Dir Assoc,2017,18(7):564-575.
[47] Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans[J].J Nutr Health Aging,2012,16(7):601-608.
[48] Gorelick PB, Nyenhuis D, American Society of Hypertension writing group, et al. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function[J].J Am Soc Hypertens,2012,6(5):309-315.
[49] Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia:a double edged sword[J].Ageing Res Rev,2009,8(2):61-70.
[50] 中国心血管病预防指南写作组,中华心血管病杂志编辑委员会.中国心血管病预防指南(2017)[J].中华心血管病杂志,2018,46(1):10-25.
[51] Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years:a randomized clinical trial[J].JAMA,2016,315(24):2673-2682.
[52] Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease[J].N Engl J Med,2016,374(21):2009-2020.
[53] Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis[J].Ann Intern Med,2015,162(3):184-191.
[54] Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control[J].N Engl J Med,2015,373(22):2103-2116.
[55] Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death:a systematic review and meta-analysis[J].Lancet,2016,387(10022):957-967.
[56] Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older[J].N Engl J Med,2008,358(18):1887-1898.
[57] Beckett N, Peters R, Leonetti G, et al. Subgroup and per-protocol analyses from the hypertension in the very elderly trial[J].J Hypertens,2014,32(7):1478-1487.
[58] Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research group[J].N Engl J Med,2001,344(1):3-10.
[59] Midgley JP, Matthew AG, Greenwood CM, et al. Effect of reduced dietary sodium on blood pressure:a meta-analysis of randomized controlled trials[J].JAMA,1996,275(20):1590-1597.
[60] Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the trial of nonpharmacologic interventions in the elderly (TONE)[J].Arch Intern Med,2001,161(5):685-693.
[61] Smith SR, Klotman PE, Svetkey LP. Potassium chloride lowers blood pressure and causes natriuresis in older patients with hypertension[J].J Am Soc Nephrol,1992,2(8):1302-1309.
[62] Fotherby MD, Potter JF. Potassium supplementation reduces clinic and ambulatory blood pressure in elderly hypertensive patients[J].J Hypertens,1992,10(11):1403-1408.
[63] Cononie CC, Graves JE, Pollock ML, et al. Effect of exercise training on blood pressure in 70- to 79-yr-old men and women[J].Med Sci Sports Exerc,1991,23(4):505-511.
[64] Dengel DR, Galecki AT, Hagberg JM, et al. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men[J].Am J Hypertens,1998,11(12):1405-1412.
[65] Taylor DH Jr, Hasselblad V, Henley SJ, et al. Benefits of smoking cessation for longevity[J].Am J Public Health,2002,92(6):990-996.
[66] Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke[J].Circulation,1997,96(4):1089-1096.
[67] Jaubert MP, Jin Z, Russo C, et al. Alcohol consumption and ambulatory blood pressure: a community-based study in an elderly cohort[J].Am J Hypertens,2014,27(5):688-694.
[68] Bansil P, Kuklina EV, Merritt RK, et al. Associations between sleep disorders, sleep duration, quality of sleep, and hypertension: results from the national health and nutrition examination survey,2005 to 2008[J].J Clin Hypertens (Greenwich),2011,13(10):739-743.
[69] Sheng CS, Cheng YB, Wei FF, et al. Diurnal blood pressure rhythmicity in relation to environmental and genetic cues in untreated referred patients[J].Hypertension,2017,69(1):128-135.
[70] Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis[J].JAMA,2003,289(19):2534-2544.
[71] Allhat officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)[J].JAMA,2002,288(23):2981-2997.
[72] Julius S, Weber MA, Kjeldsen SE, et al. The valsartan antihypertensive long-term use evaluation (VALUE) trial: outcomes in patients receiving monotherapy[J].Hypertension,2006,48(3):385-391.
[73] Ferrucci L, Guralnik JM, Pahor M, et al. Hospital diagnoses, medicare charges, and nursing home admissions in the year when older persons become severely disabled[J].JAMA,1997,277(9):728-734.
[74] Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003[J].Arch Intern Med,2008,168(4):418-424.
[75] Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic:prevalence, incidence rate, lifetime risk and prognosis of heart failure: the Rotterdam study[J].Eur Heart J,2004,25(18):1614-1619.
[76] Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes[J].Diabetes Care,2004,27(3):699-703.
[77] Antihypertensive lipid-lowering treatment to prevent heart attack trial collaborative research group. Diuretic versus alpha-blocker as first-step antihypertensive therapy:final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)[J].Hypertension,2003,42(3):239-246.
[78] Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease:meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J].BMJ,2009,338:b1665.
[79] Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. head-to-head comparisons of various classes of antihypertensive drugs-overview and meta-analyses[J].J Hypertens,2015,33(7):1321-1341.
[80] Peart S. Results of MRC (UK) trial of drug therapy for mild hypertension[J].Clin Invest Med,1987,10(6):616-620.
[81] Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial[J].Lancet,2008,372(9638):547-553.
[82] Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events[J].N Engl J Med,2008,358(15):1547-1559.
[83] Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention:principal results of a prospective randomized controlled study (MOSES)[J].Stroke,2005,36(6):1218-1226.
[84] Group PC. Post-stroke antihypertensive treatment study. A preliminary result[J].Chin Med J (Engl),1995,108(9):710-717.
[85] Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators[J].Lancet,1997,350(9080):757-764.
[86] Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE)[J].J Hypertens,1996,14(10):1237-1245.
[87] Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT)[J].Lancet,2000,356(9227):366-372.
[88] Liu L, Zhang Y, Liu G, et al. The felodipine event reduction (FEVER) study:a randomized long-term placebo-controlled trial in Chinese hypertensive patients[J].J Hypertens,2005,23(12):2157-2172.
[89] Ma W, Zhao L, Hua Q, et al. A18046 Levamlodipine maleate or amlodipinebesylate for treatment of hypertension: a comparative effectiveness research[J].J Hypertens,2018,36:e255.
[90] Progress collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack[J].Lancet,2001,358(9287):1033-1041.
[91] Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke:the PROGRESS trial[J].J Hypertens,2006,24(6):1201-1208.
[92] Patel A, Group AC, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial[J].Lancet,2007,370(9590):829-840.
[93] Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis[J].Lancet,2005,366(9496):1545-1553.
[94] Blood pressure lowering treatment trialists collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials[J].BMJ,2008,336(7653):1121-1123.
[95] Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure:meta-analysis on 11 000 participants from 42 trials[J].Am J Med,2009,122(3):290-300.
[96] MacDonald TM, Williams B, Webb DJ, et al. Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension:a double-blind randomized controlled trial[J].J Am Heart Assoc,2017,6(11):e006986.
[97] Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease[J].N Engl J Med,2016,374(21):2032-2043.
[98] Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide[J].J Clin Hypertens (Greenwich),2011,13(6):404-412.
[99] Volpe M, Christian Rump L, Ammentorp B, et al. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination[J].Clin Drug Investig,2012,32(10):649-664.
[100] Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs:analysis of 354 randomised trials[J].BMJ,2003,326(7404):1427.
[101]Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients[J].N Engl J Med,2008,359(23):2417-2428.
[102]Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol[J].Lancet,2002,359(9311):995-1003.
[103]Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial[J].Lancet,2004,363(9426):2022-2031.
[104]Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes[J].N Engl J Med,2012,367(23):2204-2213.
[105]Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy[J].N Engl J Med,2013,369(20):1892-1903.
[106]Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance:a meta-analysis[J].Am J Med,2007,120(8):713-719.
[107]王馨,段雪英,王增武,等.社区复方制剂抗高血压治疗研究:2年干预效果分析[J].中国循环杂志,2015,30(5):449-454.
[108]中国老年医学学会高血压分会,中国医师协会高血压专业委员会. 复方利血平氨苯蝶啶片临床应用中国专家共识[J].中华高血压杂志,2016,24(9):822-826.
[109]王鸿懿,孙宁玲,荆珊,等.复方利血平氨苯蝶啶片(降压0号)与吲达帕胺治疗原发性高血压患者的疗效和安全性:一项随机对照临床研究[J].中华高血压杂志,2016,24(9):857-862.
[110]Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the systolic blood pressure intervention trial (SPRINT)[J].Clin Trials,2014,11(5):532-546.
[111]Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the action to control cardiovascular risk in diabetes (ACCORD) trial[J].Am J Cardiol,2007,99(12A):44i-55i.
[112]Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study[J].BMJ,2015,350-158.
[113]Brennan T, Spettell C, Villagra V, et al. Disease management to promote blood pressure control among African Americans[J].Popul Health Manag,2010,13(2):65-72.
[114] Bosworth HB, Olsen MK, Grubber JM, et al. Two self-management interventions to improve hypertension control:a randomized trial[J].Ann Intern Med,2009,151(10):687-695.
[115]Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pressure management and improved blood pressure control:results from a randomized controlled trial[J].Arch Intern Med,2011,171(13):1173-1180.
[116]Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control:a randomized controlled trial[J].JAMA,2008,299(24):2857-2867.
[117]Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems:the adherence and intensification of medications cluster randomized, controlled pragmatic trial[J].Circulation,2012,125(23):2863-2872.
[118]Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control:a cluster randomized clinical trial[J].JAMA,2013,310(1):46-56.
[119]Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage[J].N Engl J Med,2013,368(25):2355-2365.
[120]Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage[J].Eur J Neurol,2013,20(9):1277-1283.
[121]Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke:a Chinese trial and a systematic review of the literature[J].Hypertens Res,2009,32(11):1032-1040.
[122]Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients:an INVEST substudy[J].Am J Med,2010,123(8):719-726.
[123]Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes:updated systematic review and meta-analysis[J].Lancet,2016,387(10017):435-443.
[124]Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America[J].J Am Coll Cardiol,2016,68(13):1476-1488.
[125]Zheng Y, Cai GY, Chen XM, et al. Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients[J].Chin Med J (Engl),2013,126(12):2276-2280.
[126]Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension[J].Am J Med,2012,125(1):14-22.
[127]He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials[J].BMJ,2013,346:f1325.
[128]Chopra S, Cherian D, Jacob JJ. The thyroid hormone, parathyroid hormone and vitamin D associated hypertension[J].Indian J Endocrinol Metab,2011,15 Suppl 4:S354-360.
[129]Bosworth C, Sachs MC, Duprez D, et al. Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis[J].Clin Endocrinol (Oxf),2013,79(3):429-436.
[130]Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels-updated overview and meta-analyses of randomized trials[J].J Hypertens,2016,34(4):613-622.
[131]Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The adverse experience committee; and the multicenter diltiazem postinfarction research group[J].Circulation,1991,83(1):52-60.
[132]Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction:a randomized clinical trial[J].JAMA,2013,309(12):1268-1277.
[133]Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population[J].J Am Coll Cardiol,2014,64(6):588-597.
[134]Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly:valsartan in elderly isolated systolic hypertension study[J].Hypertension,2010,56(2):196-202.
[135]Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and mortality in U.S. veterans with chronic kidney disease:a cohort study[J].Ann Intern Med,2013,159(4):233-242.
[136]Weiss JW, Peters D, Yang X, et al. Systolic BP and mortality in older adults with CKD[J].Clin J Am Soc Nephrol,2015,10(9):1553-1559.
[137]Flack JM, Calhoun D, Schiffrin EL. The New ACC/AHA hypertension guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults[J].Am J Hypertens,2018,31(2):133-135.
[138]Becker GJ, Wheeler DC, Zeeuw DD, et al. Kidney disease: improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease[J].Kidney Intern Suppl,2012,2(5):337-414.
[139]Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program[J].Am J Cardiol,2003,91(10A):28G-34G.
[140]Tomiyama H, Doba N. ALLHAT(antihypertensive and lipid lowering treatment to prevent heart attack trial)[J].Nihon Rinsho,2001,59(Suppl 3):S393-397.
[141]Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes[J].N Engl J Med,2008,359(15):1565-1576.
[142]Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials[J].Circulation,2011,123(24):2799-2810.
[143]Ferrannini E, Cushman WC. Diabetes and hypertension:the bad companions[J].Lancet,2012,380(9841):601-610.
[144]Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus:systematic review and meta-analyses[J].BMJ,2016,352:i717.
[145]Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis[J].JAMA,2015,313(6):603-615.
[146]ACCORD study group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus[J].N Engl J Med,2010,362(17):1575-1585.
[147]Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials[J].J Hypertens,2017,35(5):922-944.
[148]Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin Ⅱ receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial:clinical implications and limitations[J].J Am Soc Nephrol,2005,16(10):3027-3037.
[149]Heart outcomes prevention evaluation study investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients[J].N Engl J Med,2000,342(3):145-153.
[150]Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J,2013,34(28):2159-2219.
[151]Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension[J].Can J Cardiol,2013,29(5):528-542.
[152]Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease:a systematic review and meta-analysis[J].CMAJ,2013,185(11):949-957.
[153]Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes[J].J Am Coll Cardiol,2010,56(1):77-85.
[154]Nathan S, Pepine CJ, Bakris GL. Calcium antagonists:effects on cardio-renal risk in hypertensive patients[J].Hypertension,2005,46(4):637-642.
[155]Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes[J].Am J Cardiol,2005,95(1):29-35.
[156]中华医学会内分泌学分会. 中国糖尿病患者血压管理的专家共识[J].中华内分泌代谢杂志,2012,28(8):614-618.
[157]比索洛尔多中心研究协作组.国产比索洛尔对高血压2型糖尿病患者糖代谢的影响[J].中华内科杂志,2005,44(7):503-505.
[158]Yang W, Zhou YJ, Fu Y, et al. A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly[J].Am J Med Sci,2015,350(2):109-115.
[159]Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research[J].Hypertension,2008,51(6):1403-1419.
[160]Hla KM, Feussner JR. Screening for pseudohypertension. A quantitative, noninvasive approach[J].Arch Intern Med,1988,148(3):673-676.
[161]Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women[J].Hypertension,2005,46(3):500-507.
[162]Conlin PR, Moore TJ, Swartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients[J].Hypertension,2000,36(3):461-465.
[163]Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients≥65 years of age with systemic hypertension and osteoarthritis[J].Am J Cardiol,2002,90(9):959-963.
[164]Mansoor GA. Herbs and alternative therapies in the hypertension clinic[J].Am J Hypertens,2001,14(9 Pt 1):971-975.
[165]Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess[J].Endocrinol Metab Clin North Am,1994,23(2):359-377.
[166]Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension:results from a randomized trial[J].Hypertension,2009,54(3):475-481.
[167]Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemadynamic changes in resistance hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanism substudies[J].Lancet Diabetes Endocrinol,2018,6(6):464-475.
[168]Chiang CE, Wang TD, Ueng KC, et al. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension[J].J Chin Med Assoc,2015,78(1):1-47.
[169]Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial[J].Lancet,2015,386(10008):2059-2068.
[170]Rodilla E, Costa JA, Perez-Lahiguera F, et al. Spironolactone and doxazosin treatment in patients with resistant hypertension[J].Rev Esp Cardiol,2009,62(2):158-166.
[171]Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J].Hypertension,2018,71(6):e13-e115.
[172]Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension:results from the double-blind, randomized, placebo-controlled rheos pivotal trial[J].J Am Coll Cardiol,2011,58(7):765-773.
[173]Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension:results of long-term follow-up in the Rheos Pivotal trial[J].J Am Soc Hypertens,2012,6(2):152-158.
[174]Geisler BP, Egan BM, Cohen JT, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension[J].J Am Coll Cardiol,2012,60(14):1271-1277.
[175]Rosa J, Widimsky P, Waldauf P, et al. Role of adding spironolactone and renal denervation in true resistant hypertension:one-year outcomes of randomized PRAGUE-15 study[J].Hypertension,2016,67(2):397-403.
[176]Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension[J].N Engl J Med,2014,370(15):1393-1401.
[177]中国医师协会急诊医师分会,中国高血压联盟,北京高血压防治协会.中国急诊高血压诊疗专家共识(2017修订版)[J].中国急救医学,2018,38(1):1-13.
[178]Manning L, Robinson TG, Anderson CS. Control of blood pressure in hypertensive neurological emergencies[J].Curr Hypertens Rep,2014,16(6):436.
[179]Price RS, Kasner SE. Hypertension and hypertensive encephalopathy[J].Handb Clin Neurol,2014,119:161-167.
[180]Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial[J].Lancet Neurol,2008,7(5):391-399.
[181]Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage[J].N Engl J Med,2016,375(11):1033-1043.
[182]Togashi K, Joffe AM, Sekhar L, et al. Randomized pilot trial of intensive management of blood pressure or volume expansion in subarachnoid hemorrhage (IMPROVES)[J].Neurosurgery,2015,76(2):125-135.
[183]Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2015,46(7):2032-2060.
[184]Lee M, Ovbiagele B, Hong KS, et al. Effect of blood pressure lowering in early ischemic stroke: meta-analysis[J].Stroke,2015,46(7):1883-1889.
[185]中华医学会神经病学分会,中华医学会神经病学分会脑血管病血组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
[186]Ohishi M, Takagi T, Ito N, et al. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients:an amlodipine-to-benidipine changeover (ABC) study[J].Hypertens Res,2007,30(9):797-806.
[187]Hasebe N, Kikuchi K, Group NCS. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (nifedipine and candesartan combination) study[J].J Hypertens,2005,23(2):445-453.
[188]Nonaka K, Ubara Y, Sumida K, et al. Clinical and pathological evaluation of hypertensive emergency-related nephropathy[J].Intern Med,2013,52(1):45-53.
[189]Dupont M, Mullens W, Finucan M, et al. Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment[J].Eur J Heart Fail,2013,15(4):433-440.
[190]Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure:results of the a study of blood pressure control in acute heart failure-a pilot study (PRONTO)[J].Am Heart J,2014,167(4):529-536.
[191]Yang W, Zhou YJ, Fu Y, et al. Efficacy and safety of intravenous urapidil for older hypertensive patients with acute heart failure: a multicenter randomized controlled trial[J].Yonsei Med J,2017,58(1):105-113.
[192]Listed N. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First international study of infarct survival collaborative group[J].Lancet,1986,328(8498):57-66.
[193]Listed N. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase Ⅱ trial. The TIMI study group[J].N Engl J Med,1989,320(10):618-627.
[194]Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension[J].Eur Heart J,2018,39(33):3021-3104.
[195]Erbel R, Aboyans V, Boileau C, et al. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases:document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The task force for the diagnosis and treatment of aortic diseases of the European Society of Cardiology (ESC)[J].Eur Heart J,2014,35(41):2873-2926.
[196]Kistler PM, Sanders P, Fynn S, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age[J].J Am Coll Cardiol,2004,44(1):109-116.
[197]January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2014,64(21):e1-76.
[198]Aronsson M, Svennberg E, Rosenqvist M, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording[J].Europace,2015,17(7):1023-1029.
[199]Rizos T, G ntner J, Jenetzky E, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke[J].Stroke,2012,43(10):2689-2694.
[200]Levin LA, Husberg M, Sobocinski PD, et al. A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke[J].Europace,2015,17(2):207-214.
[201]Wachtell K, Lehto M, Gerdts E, et al. Angiotensin Ⅱ receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study[J].J Am Coll Cardiol,2005,45(5):712-719.
[202]Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias:a consensus document from the European Heart Rhythm Association (EHRA) and ESC council on hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)[J].Europace,2017,19(6):891-911.
[203]Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (antihypertensive and lipid-lowering treatment to prevent heart attack trial)[J].J Am Coll Cardiol,2009,54(22):2023-2031.
[204]Marott SC, Nielsen SF, Benn M, et al. Antihypertensive treatment and risk of atrial fibrillation:a nationwide study[J].Eur Heart J,2014,35(18):1205-1214.
[205]Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?[J].J Am Coll Cardiol,2015,65(7):635-642.
[206]Lip GYH, Skj?th F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score[J].J Am Coll Cardiol,2015,65(14):1385-1394.
[207]Felmeden DC, Lip GY. Antithrombotic therapy in hypertension:a cochrane systematic review[J].J Hum Hypertens,2005,19(3):185.
[208]Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study[J].Eur Heart J,2012,33(12):1500-1510.
[209]Dix P, Howell S. Survey of cancellation rate of hypertensive patients undergoing anaesthesia and elective surgery[J].Br J Anaesth,2002,86(6):789-793.
[210]Haas CE, Leblanc JM. Acute postoperative hypertension:a review of therapeutic options[J].Am J Health Syst Pharm,2004,61(16):1674-1675.
[211]Cheung AT. Exploring an optimum intra/postoperative management strategy for acute hypertension in the cardiac surgery patient[J].J Card Surg,2010,21(S1):S8-14.
[212]Kwon S, Thompson R, Florence M, et al. Beta-blocker continuation after noncardiac surgery:a report from the surgical care and outcomes assessment program[J].Arch Surg,2012,147(5):467-473.
[213]Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope:executive summary:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2017,70(5):620-663.
[214]Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome[J].Clin Auton Res,2011,21(2):69-72.
[215]Joseph A, Wanono R, Flamant M, et al. Orthostatic hypotension: a review[J].Nephrol Ther,2017,13(Suppl 1):S55-67.
[216]Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension[J].J Neurol,2017,264(8):1567-1582.
[217]Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults:the atherosclerosis risk in communities(ARIC) study[J].Circulation,2006,114(7):630-636.
[218]Ricci F, Fedorowski A, Radico F, et al. Cardiovascular morbidity and mortality related to orthostatic hypotension:a meta-analysis of prospective observational studies[J].Euro Heart J,2015,36(25):1609-1617.
[219]Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents[J].Am J Med,2000,108(2):106-111.
[220]Arnold AC, Raj SR. Orthostatic hypotension: a practical approach to investigation and management[J].Can J Cardiol,2017,33(12):1725-1728.
[221]Ong HL, Abdin E, Seow E, et al. Prevalence and associative factors of orthostatic hypotension in older adults: results from the well-being of the Singapore elderly (WiSE) study[J].Arch Gerontol Geriatr,2017,72(24):146-152.
[222]Cyndya S, Lewis Arnold L, Italo B. ASH position paper:evaluation and treatment of orthostatic hypotension[J].J Clin Hypertens,2013,15(3):147-153.
[223]Brignole M, Moya A, de Lange FJ, et al. 2018 ESC guidelines for the diagnosis and management of syncope[J].Eur Heart J,2018,39(21):1883-1948.
[224]Chisholm P, Anpalahan M. Orthostatic hypotension: pathophysiology, assessment, treatment and the paradox of supine hypertension[J].Intern Med J,2017,47(4):370-379.
[225]Arnold AC, Okamoto LE, Alfredo G, et al. Angiotensin Ⅱ, independent of plasma renin activity, contributes to the hypertension of autonomic failure[J].Hypertension,2013,61(3):701-706.
[226]Shannon J, Jordan J, Costa F, et al. The hypertension of autonomic failure and its treatment[J].Hypertension,1997,30(5):1062-1067.
[227]Staessen JA, Gasowski J, Ji GW, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials[J].Lancet,2000,355(9207):865-872.
[228]华琦,皮林,李东宝,等.高血压病患者昼夜血压节律对心脏结构和功能的影响[J].中华心血管病杂志,2003,31(8):594-596.
[229]Hansen TW, Li Y, Boggia J, et al. Predictive role of the nighttime blood pressure[J].Hypertension,2011,57(1):3-10.
[230]Metoki H, Ohkubo TM, Asayama K, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study[J].Hypertension,2006,47(2):149-154.
[231]Paolo V, Fabio A, Giovanni M, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications[J].Hypertension,2012,60(1):34-42.
[232]Hermida RC, Ayala DE, Mojón A, et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk[J].J Am Coll Cardiol,2011,58(11):1165-1173.
[233]Park S, Jastremski CA, Wallace JP. Time of day for exercise on blood pressure reduction in dipping and nondipping hypertension[J].J Hum Hypertens,2005,19(8):597-605.
[234]Takeda A, Toda T, Fujii T, et al. Bedtime administration of long-acting antihypertensive drugs restores normal nocturnal blood pressure fall in nondippers with essential hypertension[J].Clin Exp Nephrol,2009,13(5):467-472.
[235]路岩,朱丹,郝宇,等.住院老年高血压患者伴发餐后低血压的临床观察[J].中华高血压杂志,2017,25(2):145-151.
[236]Kazushi D, Kazuyo I, Iwao S, et al. Effects of daily water drinking on orthostatic and postprandial hypotension in patients with multiple system atrophy[J].J Neurol,2007,254(6):735-740.
[237]Gentilcore D, Hausken T, Meyer JH, et al. Effects of intraduodenal glucose, fat, and protein on blood pressure, heart rate, and splanchnic blood flow in healthy older subjects[J].Am J Clin Nutr,2008,87(1):156-161.
[238]Nair S, Visvanathan R, Gentilcore D. Intermittent walking: a potential treatment for older people with postprandial hypotension[J].J Am Med Dir Assoc,2015,16(2):160-164.
[239]Oberman AS, Harada RK, Gagnon MM, et al. Effects of postprandial walking exercise on meal-related hypotension in frail elderly patients[J].Am J Cardiol,1999,84(9):1130-1132.
[240]Qiao W, Li J, Li Y, et al. Acarbose, the α-glucosidase inhibitor, attenuates the blood pressure and splanchnic blood flow responses to meal in elderly patients with postprandial hypotension concomitant with abnormal glucose metabolism[J].Blood Press Monit,2016,21(1):38-42.
[241]谢志泉,林仲秋,王银玲,等. 广州军队高龄老年高血压的特点[J].中华高血压杂志,2011,19(6):557-560.
[242]王银玲,谢志泉,邓玉,等. 中老年男性高血压患者血压晨峰临床分析[J].中华内科杂志,2011,50(12):1030-1033.
[243]孙宁玲,喜杨,荆珊,等. 左旋氨氯地平的时间药理学对纠正老年非杓型高血压的作用[J].中华高血压杂志,2007,15(1):26-29.
[244]许耀,郝云霞,崔爱东,等. 硝苯地平控释片不同时间给药对高血压患者血压变异性的影响[J].中华高血压杂志,2015,23(6):543-548.
[245]Charach G, Rabinovich PM. Seasonal changes in blood pressure and frequency of related complications in elderly israeli patients with essential hypertension[J].Gerontology,2004,50(5):315-321.
[246]苏海.血压的季节性变化[J].中华高血压杂志,2009,17(10):880-883.
[247]Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study[J].J Am Coll Cardiol,2005,46(3):508-515.
[248]Miki H, Akira M, Kei A, et al. Relationship of dysregulation of glucose metabolism with white-coat hypertension: the Ohasama study[J].Hypertens Res,2010,33(9):937-943.
[249]Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension:analysis from the Dallas heart study[J].J Am Soc Hypertens,2015,66(20):2159-2169.
[250]王磊,李南方,周克明,等. 难以控制的高血压628例病因分析[J].中华心血管病杂志,2009,37(2):138-141.
[251]上海慢性肾脏病早发现及规范化诊治与示范项目专家组.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志,2017,37(1):28-34.
[252]Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism:case detection, diagnosis, and treatment:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2016,101(5):1889-1916.
[253]中华医学会内分泌学分会肾上腺学组. 原发性醛固酮增多症诊断治疗的专家共识[J].中华内分泌代谢杂志,2016,32(3):188-195.
[254]中国医疗保健国际交流促进会血管疾病高血压分会专家共识起草组. 肾动脉狭窄的诊断和处理中国专家共识[J].中国循环杂志,2017,32(9):835-844.
[255]Abela R, Ivanova S, Lidder S, et al. An analysis comparing open surgical and endovascular treatment of atherosclerotic renal artery stenosis[J].Eur J Vasc Endovasc Surg,2009,38(6):666-675.
[256]中国医师协会高血压专业委员会,中华医学会呼吸病学分会睡眠呼吸障碍学组. 阻塞性睡眠呼吸暂停相关性高血压临床诊断和治疗专家共识[J].中华高血压杂志,2012,20(12):1119-1124.
[257]Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005[J].Sleep,2005,28(4):499-521.
[258]中华医学会呼吸病学分会睡眠呼吸障碍学组.阻塞性睡眠呼吸暂停低通气综合征患者持续气道正压通气临床应用专家共识(草案)[J].中华结核和呼吸杂志,2012,35(1):13-18.
[259]王晓宇,孙丽,李悦.药源性高血压[J].中华高血压杂志,2012,20(12):1188-1190.
[260]Virdis A, Ghiadoni L, Taddei S, et al. Clinical management of drug-induced hypertension: 2013 practical recommendations of the Italian Society of Hypertension (SIIA)[J].High Blood Press Cardiovasc Prev,2014,21(1):77-79.
[2] 王薇,赵冬. 中国老年人高血压的流行病学[J].中华老年医学杂志,2005,24(4):246-247.
[3] 李立明,饶克勤,孔灵芝,等. 中国居民2002年营养与健康状况调查[J].中华流行病学杂志,2005,26(7):478-484.
[4] 李苏宁,陈祚,王增武,等. 我国老年人高血压现状分析[J].中华高血压杂志,2019,27(2):140-148.
[5] Wu Y, Huxley R, Li L, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002[J].Circulation,2008,118(25):2679-2686.
[6] 范国辉,王增武,张林峰,等. 2013年北方四区县农村高血压患病率,知晓率,治疗率和控制率调查[J].中华医学杂志,2015,95(8):616-620.
[7] Yang L, Yan J, Tang X, et al. Prevalence, awareness, treatment, control and risk factors associated with hypertension among adults in Southern China, 2013[J].PLoS One,2016,11(1):e0146181.
[8] Gu H, Li W, Yang J, et al. Hypertension prevalence, awareness, treatment and control among Han and four ethnic minorities (Uygur, Hui, Mongolian and Dai) in China[J].J Hum Hypertens,2015,29(9):555-560.
[9] 王志军,柯元南,周建芝. 老年高血压患者的血压控制现状及影响因素分析[J].中华老年心脑血管病杂志,2008,10(4):246-249.
[10] Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly:a report of the American College of Cardiology foundation task force on clinical expert consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension[J].J Am Soc Hypertens,2011,5(4):259-352.
[11] 吴锡桂,段秀芳,黄广勇,等. 我国老年人群单纯性收缩期高血压患病率及影响因素[J].中华心血管病杂志,2003,31(6):456-459.
[12] 中国老年医学学会高血压分会. 高龄老年人血压管理中国专家共识[J].中华高血压杂志,2015,23(12):1127-1134.
[13] Franklin SS, Wilkinson IB, McEniery CM. Unusual hypertensive phenotypes:what is their significance?[J].Hypertension,2012,59(2):173-178.
[14] Sheng CS, Liu M, Zeng WF, et al. Four-limb blood pressure as predictors of mortality in elderly Chinese[J].Hypertension,2013,61(6):1155-1160.
[15] Stergiou GS, Siontis KC, Ioannidis JP. Home blood pressure as a cardiovascular outcome predictor:it's time to take this method seriously[J].Hypertension,2010,55(6):1301-1303.
[16] Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home:a summary report of the second international consensus conference on home blood pressure monitoring[J].J Hypertens,2008,26(8):1505-1526.
[17] 中国医师协会高血压专业委员会,中国高血压联盟,中华医学会心血管病学分会.家庭血压监测中国专家共识[J].中华高血压杂志,2012,20(6):525-529.
[18] 中国高血压联盟,中国医师协会高血压专业委员会血压测量与监测工作委员会,《中华高血压杂志》编委会.动态血压监测临床应用中国专家共识[J].中华高血压杂志,2015,23(8):727-730.
[19] Parati G, Stergiou G, O'Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring[J].J Hypertens,2014,32(7):1359-1366.
[20] Li Y, Staessen JA, Lu L, et al. Is isolated nocturnal hypertension a novel clinical entity? Findings from a Chinese population study[J].Hypertension,2007,50(2):333-339.
[21] 中国老年医学学会高血压分会. 老年人异常血压波动临床诊疗中国专家共识[J].中华高血压杂志,2017,25(2):132-139.
[22] 华琦,朱玉仑. 超声心动图检测年龄进程中心功能的衍变特点[J].中华心血管病杂志,1990,18(4):212-214.
[23] 中国高血压防治指南修订委员会. 中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-743.
[24] 赵冬,吴兆苏,王薇,等. 中国11省市队列人群基线血压和7年累积心血管病发病危险的前瞻性研究[J].中华心血管病杂志,2001,29(10):612-617.
[25] Gu D, Gupta A, Muntner P, et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China:results from the international collaborative study of cardiovascular disease in Asia (InterAsia)[J].Circulation,2005,112(5):658-665.
[26] 刘军,王薇,刘静,等. 门诊高血压病患者合并心血管病危险因素及血压控制现况[J].中华心血管病杂志,2013,41(12):1050-1054.
[27] Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical paradigm-issues and controversies[J].J Gerontol A Biol Sci Med Sci,2007,62(7):731-737.
[28] Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults[J].J Am Coll Cardiol,2014,63(8):747-762.
[29] 李建华,范利,赵婷,等.老年高血压患者发生衰弱对预后的影响[J].中华老年多器官疾病杂志,2018,17(5):324-328.
[30] Odden MC, Covinsky KE, Neuhaus JM, et al. The association of blood pressure and mortality differs by self-reported walking speed in older Latinos[J].J Gerontol A Biol Sci Med Sci,2012,67(9):977-983.
[31] Odden MC, Peralta CA, Haan MN, et al. Rethinking the association of high blood pressure with mortality in elderly adults:the impact of frailty[J].Arch Intern Med,2012,172(15):1162-1168.
[32] Peralta CA, Katz R, Newman AB, et al. Systolic and diastolic blood pressure, incident cardiovascular events, and death in elderly persons:the role of functional limitation in the cardiovascular health study[J].Hypertension,2014,64(3):472-480.
[33] Post Hospers G, Smulders YM, Maier AB, et al. Relation between blood pressure and mortality risk in an older population:role of chronological and biological age[J].J Intern Med,2015,277(4):488-497.
[34] Ravindrarajah R, Hazra NC, Hamada S, et al. Systolic blood pressure trajectory, frailty, and all-cause mortality >80 years of age:cohort study using electronic health records[J].Circulation,2017,135(24):2357-2368.
[35] Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG):a double-blind, placebo controlled trial[J].Lancet Neurol,2008,7(8):683-689.
[36] Pajewski NM, Williamson JD, Applegate WB, et al. Characterizing frailty status in the systolic blood pressure intervention trial[J].J Gerontol A Biol Sci Med Sci,2016,71(5):649-655.
[37] Williamson JD, Supiano MA, Pajewski NM. Intensive vs standard blood pressure control for older adults-reply[J].JAMA,2016,316(18):1923.
[38] Benetos A, Bulpitt CJ, Petrovic M, et al. An Expert opinion from the European Society of Hypertension-European Union Geriatric Medicine Society working group on the management of hypertension in very old, frail subjects[J].Hypertension,2016,67(5):820-825.
[39] Morley JE, Vellas B, van Kan GA, et al. Frailty consensus:a call to action[J].J Am Med Dir Assoc,2013,14(6):392-397.
[40] Bursztyn M. Hypertension, its treatment, frailty, falls, and mortality[J].Hypertension,2017,70(2):253-254.
[41] 中华医学会老年医学分会.老年患者衰弱评估与干预中国专家共识[J].中华老年医学杂志,2017,36(3):251-256.
[42] Bromfield SG, Ngameni CA, Colantonio LD, et al. Blood pressure, antihypertensive polypharmacy, frailty, and risk for serious fall injuries among older treated adults with hypertension[J].Hypertension,2017,70(2):259-266.
[43] Kojima G. Frailty defined by FRAIL scale as a predictor of mortality:a systematic review and meta-analysis[J].J Am Med Dir Assoc,2018,19(6):480-483.
[44] Yano Y, Inokuchi T, Kario K. Walking speed is a useful marker of frailty in older persons[J].JAMA Intern Med,2013,173(4):325-326.
[45] Fried LP, Tangen CM, Walston J, et al. Frailty in older adults:evidence for a phenotype[J].J Gerontol A Biol Sci Med Sci,2001,56(3):M146-156.
[46] Dent E, Lien C, Lim WS, et al. The Asia-Pacific clinical practice guidelines for the management of frailty[J].J Am Med Dir Assoc,2017,18(7):564-575.
[47] Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans[J].J Nutr Health Aging,2012,16(7):601-608.
[48] Gorelick PB, Nyenhuis D, American Society of Hypertension writing group, et al. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function[J].J Am Soc Hypertens,2012,6(5):309-315.
[49] Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia:a double edged sword[J].Ageing Res Rev,2009,8(2):61-70.
[50] 中国心血管病预防指南写作组,中华心血管病杂志编辑委员会.中国心血管病预防指南(2017)[J].中华心血管病杂志,2018,46(1):10-25.
[51] Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years:a randomized clinical trial[J].JAMA,2016,315(24):2673-2682.
[52] Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease[J].N Engl J Med,2016,374(21):2009-2020.
[53] Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis[J].Ann Intern Med,2015,162(3):184-191.
[54] Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control[J].N Engl J Med,2015,373(22):2103-2116.
[55] Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death:a systematic review and meta-analysis[J].Lancet,2016,387(10022):957-967.
[56] Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older[J].N Engl J Med,2008,358(18):1887-1898.
[57] Beckett N, Peters R, Leonetti G, et al. Subgroup and per-protocol analyses from the hypertension in the very elderly trial[J].J Hypertens,2014,32(7):1478-1487.
[58] Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research group[J].N Engl J Med,2001,344(1):3-10.
[59] Midgley JP, Matthew AG, Greenwood CM, et al. Effect of reduced dietary sodium on blood pressure:a meta-analysis of randomized controlled trials[J].JAMA,1996,275(20):1590-1597.
[60] Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the trial of nonpharmacologic interventions in the elderly (TONE)[J].Arch Intern Med,2001,161(5):685-693.
[61] Smith SR, Klotman PE, Svetkey LP. Potassium chloride lowers blood pressure and causes natriuresis in older patients with hypertension[J].J Am Soc Nephrol,1992,2(8):1302-1309.
[62] Fotherby MD, Potter JF. Potassium supplementation reduces clinic and ambulatory blood pressure in elderly hypertensive patients[J].J Hypertens,1992,10(11):1403-1408.
[63] Cononie CC, Graves JE, Pollock ML, et al. Effect of exercise training on blood pressure in 70- to 79-yr-old men and women[J].Med Sci Sports Exerc,1991,23(4):505-511.
[64] Dengel DR, Galecki AT, Hagberg JM, et al. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men[J].Am J Hypertens,1998,11(12):1405-1412.
[65] Taylor DH Jr, Hasselblad V, Henley SJ, et al. Benefits of smoking cessation for longevity[J].Am J Public Health,2002,92(6):990-996.
[66] Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke[J].Circulation,1997,96(4):1089-1096.
[67] Jaubert MP, Jin Z, Russo C, et al. Alcohol consumption and ambulatory blood pressure: a community-based study in an elderly cohort[J].Am J Hypertens,2014,27(5):688-694.
[68] Bansil P, Kuklina EV, Merritt RK, et al. Associations between sleep disorders, sleep duration, quality of sleep, and hypertension: results from the national health and nutrition examination survey,2005 to 2008[J].J Clin Hypertens (Greenwich),2011,13(10):739-743.
[69] Sheng CS, Cheng YB, Wei FF, et al. Diurnal blood pressure rhythmicity in relation to environmental and genetic cues in untreated referred patients[J].Hypertension,2017,69(1):128-135.
[70] Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis[J].JAMA,2003,289(19):2534-2544.
[71] Allhat officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)[J].JAMA,2002,288(23):2981-2997.
[72] Julius S, Weber MA, Kjeldsen SE, et al. The valsartan antihypertensive long-term use evaluation (VALUE) trial: outcomes in patients receiving monotherapy[J].Hypertension,2006,48(3):385-391.
[73] Ferrucci L, Guralnik JM, Pahor M, et al. Hospital diagnoses, medicare charges, and nursing home admissions in the year when older persons become severely disabled[J].JAMA,1997,277(9):728-734.
[74] Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003[J].Arch Intern Med,2008,168(4):418-424.
[75] Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic:prevalence, incidence rate, lifetime risk and prognosis of heart failure: the Rotterdam study[J].Eur Heart J,2004,25(18):1614-1619.
[76] Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes[J].Diabetes Care,2004,27(3):699-703.
[77] Antihypertensive lipid-lowering treatment to prevent heart attack trial collaborative research group. Diuretic versus alpha-blocker as first-step antihypertensive therapy:final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)[J].Hypertension,2003,42(3):239-246.
[78] Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease:meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies[J].BMJ,2009,338:b1665.
[79] Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. head-to-head comparisons of various classes of antihypertensive drugs-overview and meta-analyses[J].J Hypertens,2015,33(7):1321-1341.
[80] Peart S. Results of MRC (UK) trial of drug therapy for mild hypertension[J].Clin Invest Med,1987,10(6):616-620.
[81] Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial[J].Lancet,2008,372(9638):547-553.
[82] Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events[J].N Engl J Med,2008,358(15):1547-1559.
[83] Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention:principal results of a prospective randomized controlled study (MOSES)[J].Stroke,2005,36(6):1218-1226.
[84] Group PC. Post-stroke antihypertensive treatment study. A preliminary result[J].Chin Med J (Engl),1995,108(9):710-717.
[85] Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators[J].Lancet,1997,350(9080):757-764.
[86] Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE)[J].J Hypertens,1996,14(10):1237-1245.
[87] Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT)[J].Lancet,2000,356(9227):366-372.
[88] Liu L, Zhang Y, Liu G, et al. The felodipine event reduction (FEVER) study:a randomized long-term placebo-controlled trial in Chinese hypertensive patients[J].J Hypertens,2005,23(12):2157-2172.
[89] Ma W, Zhao L, Hua Q, et al. A18046 Levamlodipine maleate or amlodipinebesylate for treatment of hypertension: a comparative effectiveness research[J].J Hypertens,2018,36:e255.
[90] Progress collaborative group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack[J].Lancet,2001,358(9287):1033-1041.
[91] Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke:the PROGRESS trial[J].J Hypertens,2006,24(6):1201-1208.
[92] Patel A, Group AC, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial):a randomised controlled trial[J].Lancet,2007,370(9590):829-840.
[93] Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis[J].Lancet,2005,366(9496):1545-1553.
[94] Blood pressure lowering treatment trialists collaboration, Turnbull F, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials[J].BMJ,2008,336(7653):1121-1123.
[95] Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure:meta-analysis on 11 000 participants from 42 trials[J].Am J Med,2009,122(3):290-300.
[96] MacDonald TM, Williams B, Webb DJ, et al. Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension:a double-blind randomized controlled trial[J].J Am Heart Assoc,2017,6(11):e006986.
[97] Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease[J].N Engl J Med,2016,374(21):2032-2043.
[98] Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide[J].J Clin Hypertens (Greenwich),2011,13(6):404-412.
[99] Volpe M, Christian Rump L, Ammentorp B, et al. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination[J].Clin Drug Investig,2012,32(10):649-664.
[100] Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs:analysis of 354 randomised trials[J].BMJ,2003,326(7404):1427.
[101]Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients[J].N Engl J Med,2008,359(23):2417-2428.
[102]Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol[J].Lancet,2002,359(9311):995-1003.
[103]Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial[J].Lancet,2004,363(9426):2022-2031.
[104]Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes[J].N Engl J Med,2012,367(23):2204-2213.
[105]Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy[J].N Engl J Med,2013,369(20):1892-1903.
[106]Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance:a meta-analysis[J].Am J Med,2007,120(8):713-719.
[107]王馨,段雪英,王增武,等.社区复方制剂抗高血压治疗研究:2年干预效果分析[J].中国循环杂志,2015,30(5):449-454.
[108]中国老年医学学会高血压分会,中国医师协会高血压专业委员会. 复方利血平氨苯蝶啶片临床应用中国专家共识[J].中华高血压杂志,2016,24(9):822-826.
[109]王鸿懿,孙宁玲,荆珊,等.复方利血平氨苯蝶啶片(降压0号)与吲达帕胺治疗原发性高血压患者的疗效和安全性:一项随机对照临床研究[J].中华高血压杂志,2016,24(9):857-862.
[110]Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the systolic blood pressure intervention trial (SPRINT)[J].Clin Trials,2014,11(5):532-546.
[111]Cushman WC, Grimm RH Jr, Cutler JA, et al. Rationale and design for the blood pressure intervention of the action to control cardiovascular risk in diabetes (ACCORD) trial[J].Am J Cardiol,2007,99(12A):44i-55i.
[112]Xu W, Goldberg SI, Shubina M, et al. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study[J].BMJ,2015,350-158.
[113]Brennan T, Spettell C, Villagra V, et al. Disease management to promote blood pressure control among African Americans[J].Popul Health Manag,2010,13(2):65-72.
[114] Bosworth HB, Olsen MK, Grubber JM, et al. Two self-management interventions to improve hypertension control:a randomized trial[J].Ann Intern Med,2009,151(10):687-695.
[115]Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pressure management and improved blood pressure control:results from a randomized controlled trial[J].Arch Intern Med,2011,171(13):1173-1180.
[116]Green BB, Cook AJ, Ralston JD, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control:a randomized controlled trial[J].JAMA,2008,299(24):2857-2867.
[117]Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems:the adherence and intensification of medications cluster randomized, controlled pragmatic trial[J].Circulation,2012,125(23):2863-2872.
[118]Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control:a cluster randomized clinical trial[J].JAMA,2013,310(1):46-56.
[119]Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage[J].N Engl J Med,2013,368(25):2355-2365.
[120]Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage[J].Eur J Neurol,2013,20(9):1277-1283.
[121]Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke:a Chinese trial and a systematic review of the literature[J].Hypertens Res,2009,32(11):1032-1040.
[122]Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients:an INVEST substudy[J].Am J Med,2010,123(8):719-726.
[123]Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes:updated systematic review and meta-analysis[J].Lancet,2016,387(10017):435-443.
[124]Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America[J].J Am Coll Cardiol,2016,68(13):1476-1488.
[125]Zheng Y, Cai GY, Chen XM, et al. Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients[J].Chin Med J (Engl),2013,126(12):2276-2280.
[126]Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension[J].Am J Med,2012,125(1):14-22.
[127]He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials[J].BMJ,2013,346:f1325.
[128]Chopra S, Cherian D, Jacob JJ. The thyroid hormone, parathyroid hormone and vitamin D associated hypertension[J].Indian J Endocrinol Metab,2011,15 Suppl 4:S354-360.
[129]Bosworth C, Sachs MC, Duprez D, et al. Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis[J].Clin Endocrinol (Oxf),2013,79(3):429-436.
[130]Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels-updated overview and meta-analyses of randomized trials[J].J Hypertens,2016,34(4):613-622.
[131]Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The adverse experience committee; and the multicenter diltiazem postinfarction research group[J].Circulation,1991,83(1):52-60.
[132]Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction:a randomized clinical trial[J].JAMA,2013,309(12):1268-1277.
[133]Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population[J].J Am Coll Cardiol,2014,64(6):588-597.
[134]Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly:valsartan in elderly isolated systolic hypertension study[J].Hypertension,2010,56(2):196-202.
[135]Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and mortality in U.S. veterans with chronic kidney disease:a cohort study[J].Ann Intern Med,2013,159(4):233-242.
[136]Weiss JW, Peters D, Yang X, et al. Systolic BP and mortality in older adults with CKD[J].Clin J Am Soc Nephrol,2015,10(9):1553-1559.
[137]Flack JM, Calhoun D, Schiffrin EL. The New ACC/AHA hypertension guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults[J].Am J Hypertens,2018,31(2):133-135.
[138]Becker GJ, Wheeler DC, Zeeuw DD, et al. Kidney disease: improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease[J].Kidney Intern Suppl,2012,2(5):337-414.
[139]Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program[J].Am J Cardiol,2003,91(10A):28G-34G.
[140]Tomiyama H, Doba N. ALLHAT(antihypertensive and lipid lowering treatment to prevent heart attack trial)[J].Nihon Rinsho,2001,59(Suppl 3):S393-397.
[141]Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes[J].N Engl J Med,2008,359(15):1565-1576.
[142]Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials[J].Circulation,2011,123(24):2799-2810.
[143]Ferrannini E, Cushman WC. Diabetes and hypertension:the bad companions[J].Lancet,2012,380(9841):601-610.
[144]Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus:systematic review and meta-analyses[J].BMJ,2016,352:i717.
[145]Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis[J].JAMA,2015,313(6):603-615.
[146]ACCORD study group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus[J].N Engl J Med,2010,362(17):1575-1585.
[147]Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials[J].J Hypertens,2017,35(5):922-944.
[148]Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin Ⅱ receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial:clinical implications and limitations[J].J Am Soc Nephrol,2005,16(10):3027-3037.
[149]Heart outcomes prevention evaluation study investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients[J].N Engl J Med,2000,342(3):145-153.
[150]Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension:the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J,2013,34(28):2159-2219.
[151]Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension[J].Can J Cardiol,2013,29(5):528-542.
[152]Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease:a systematic review and meta-analysis[J].CMAJ,2013,185(11):949-957.
[153]Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes[J].J Am Coll Cardiol,2010,56(1):77-85.
[154]Nathan S, Pepine CJ, Bakris GL. Calcium antagonists:effects on cardio-renal risk in hypertensive patients[J].Hypertension,2005,46(4):637-642.
[155]Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes[J].Am J Cardiol,2005,95(1):29-35.
[156]中华医学会内分泌学分会. 中国糖尿病患者血压管理的专家共识[J].中华内分泌代谢杂志,2012,28(8):614-618.
[157]比索洛尔多中心研究协作组.国产比索洛尔对高血压2型糖尿病患者糖代谢的影响[J].中华内科杂志,2005,44(7):503-505.
[158]Yang W, Zhou YJ, Fu Y, et al. A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly[J].Am J Med Sci,2015,350(2):109-115.
[159]Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research[J].Hypertension,2008,51(6):1403-1419.
[160]Hla KM, Feussner JR. Screening for pseudohypertension. A quantitative, noninvasive approach[J].Arch Intern Med,1988,148(3):673-676.
[161]Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women[J].Hypertension,2005,46(3):500-507.
[162]Conlin PR, Moore TJ, Swartz SL, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients[J].Hypertension,2000,36(3):461-465.
[163]Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients≥65 years of age with systemic hypertension and osteoarthritis[J].Am J Cardiol,2002,90(9):959-963.
[164]Mansoor GA. Herbs and alternative therapies in the hypertension clinic[J].Am J Hypertens,2001,14(9 Pt 1):971-975.
[165]Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess[J].Endocrinol Metab Clin North Am,1994,23(2):359-377.
[166]Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension:results from a randomized trial[J].Hypertension,2009,54(3):475-481.
[167]Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemadynamic changes in resistance hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanism substudies[J].Lancet Diabetes Endocrinol,2018,6(6):464-475.
[168]Chiang CE, Wang TD, Ueng KC, et al. 2015 guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension[J].J Chin Med Assoc,2015,78(1):1-47.
[169]Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial[J].Lancet,2015,386(10008):2059-2068.
[170]Rodilla E, Costa JA, Perez-Lahiguera F, et al. Spironolactone and doxazosin treatment in patients with resistant hypertension[J].Rev Esp Cardiol,2009,62(2):158-166.
[171]Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J].Hypertension,2018,71(6):e13-e115.
[172]Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension:results from the double-blind, randomized, placebo-controlled rheos pivotal trial[J].J Am Coll Cardiol,2011,58(7):765-773.
[173]Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension:results of long-term follow-up in the Rheos Pivotal trial[J].J Am Soc Hypertens,2012,6(2):152-158.
[174]Geisler BP, Egan BM, Cohen JT, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension[J].J Am Coll Cardiol,2012,60(14):1271-1277.
[175]Rosa J, Widimsky P, Waldauf P, et al. Role of adding spironolactone and renal denervation in true resistant hypertension:one-year outcomes of randomized PRAGUE-15 study[J].Hypertension,2016,67(2):397-403.
[176]Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension[J].N Engl J Med,2014,370(15):1393-1401.
[177]中国医师协会急诊医师分会,中国高血压联盟,北京高血压防治协会.中国急诊高血压诊疗专家共识(2017修订版)[J].中国急救医学,2018,38(1):1-13.
[178]Manning L, Robinson TG, Anderson CS. Control of blood pressure in hypertensive neurological emergencies[J].Curr Hypertens Rep,2014,16(6):436.
[179]Price RS, Kasner SE. Hypertension and hypertensive encephalopathy[J].Handb Clin Neurol,2014,119:161-167.
[180]Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial[J].Lancet Neurol,2008,7(5):391-399.
[181]Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage[J].N Engl J Med,2016,375(11):1033-1043.
[182]Togashi K, Joffe AM, Sekhar L, et al. Randomized pilot trial of intensive management of blood pressure or volume expansion in subarachnoid hemorrhage (IMPROVES)[J].Neurosurgery,2015,76(2):125-135.
[183]Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2015,46(7):2032-2060.
[184]Lee M, Ovbiagele B, Hong KS, et al. Effect of blood pressure lowering in early ischemic stroke: meta-analysis[J].Stroke,2015,46(7):1883-1889.
[185]中华医学会神经病学分会,中华医学会神经病学分会脑血管病血组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
[186]Ohishi M, Takagi T, Ito N, et al. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients:an amlodipine-to-benidipine changeover (ABC) study[J].Hypertens Res,2007,30(9):797-806.
[187]Hasebe N, Kikuchi K, Group NCS. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (nifedipine and candesartan combination) study[J].J Hypertens,2005,23(2):445-453.
[188]Nonaka K, Ubara Y, Sumida K, et al. Clinical and pathological evaluation of hypertensive emergency-related nephropathy[J].Intern Med,2013,52(1):45-53.
[189]Dupont M, Mullens W, Finucan M, et al. Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment[J].Eur J Heart Fail,2013,15(4):433-440.
[190]Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure:results of the a study of blood pressure control in acute heart failure-a pilot study (PRONTO)[J].Am Heart J,2014,167(4):529-536.
[191]Yang W, Zhou YJ, Fu Y, et al. Efficacy and safety of intravenous urapidil for older hypertensive patients with acute heart failure: a multicenter randomized controlled trial[J].Yonsei Med J,2017,58(1):105-113.
[192]Listed N. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First international study of infarct survival collaborative group[J].Lancet,1986,328(8498):57-66.
[193]Listed N. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase Ⅱ trial. The TIMI study group[J].N Engl J Med,1989,320(10):618-627.
[194]Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension[J].Eur Heart J,2018,39(33):3021-3104.
[195]Erbel R, Aboyans V, Boileau C, et al. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases:document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The task force for the diagnosis and treatment of aortic diseases of the European Society of Cardiology (ESC)[J].Eur Heart J,2014,35(41):2873-2926.
[196]Kistler PM, Sanders P, Fynn S, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age[J].J Am Coll Cardiol,2004,44(1):109-116.
[197]January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2014,64(21):e1-76.
[198]Aronsson M, Svennberg E, Rosenqvist M, et al. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording[J].Europace,2015,17(7):1023-1029.
[199]Rizos T, G ntner J, Jenetzky E, et al. Continuous stroke unit electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of paroxysmal atrial fibrillation after stroke[J].Stroke,2012,43(10):2689-2694.
[200]Levin LA, Husberg M, Sobocinski PD, et al. A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke[J].Europace,2015,17(2):207-214.
[201]Wachtell K, Lehto M, Gerdts E, et al. Angiotensin Ⅱ receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension (LIFE) study[J].J Am Coll Cardiol,2005,45(5):712-719.
[202]Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias:a consensus document from the European Heart Rhythm Association (EHRA) and ESC council on hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)[J].Europace,2017,19(6):891-911.
[203]Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (antihypertensive and lipid-lowering treatment to prevent heart attack trial)[J].J Am Coll Cardiol,2009,54(22):2023-2031.
[204]Marott SC, Nielsen SF, Benn M, et al. Antihypertensive treatment and risk of atrial fibrillation:a nationwide study[J].Eur Heart J,2014,35(18):1205-1214.
[205]Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?[J].J Am Coll Cardiol,2015,65(7):635-642.
[206]Lip GYH, Skj?th F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score[J].J Am Coll Cardiol,2015,65(14):1385-1394.
[207]Felmeden DC, Lip GY. Antithrombotic therapy in hypertension:a cochrane systematic review[J].J Hum Hypertens,2005,19(3):185.
[208]Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study[J].Eur Heart J,2012,33(12):1500-1510.
[209]Dix P, Howell S. Survey of cancellation rate of hypertensive patients undergoing anaesthesia and elective surgery[J].Br J Anaesth,2002,86(6):789-793.
[210]Haas CE, Leblanc JM. Acute postoperative hypertension:a review of therapeutic options[J].Am J Health Syst Pharm,2004,61(16):1674-1675.
[211]Cheung AT. Exploring an optimum intra/postoperative management strategy for acute hypertension in the cardiac surgery patient[J].J Card Surg,2010,21(S1):S8-14.
[212]Kwon S, Thompson R, Florence M, et al. Beta-blocker continuation after noncardiac surgery:a report from the surgical care and outcomes assessment program[J].Arch Surg,2012,147(5):467-473.
[213]Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope:executive summary:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society[J].J Am Coll Cardiol,2017,70(5):620-663.
[214]Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome[J].Clin Auton Res,2011,21(2):69-72.
[215]Joseph A, Wanono R, Flamant M, et al. Orthostatic hypotension: a review[J].Nephrol Ther,2017,13(Suppl 1):S55-67.
[216]Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension[J].J Neurol,2017,264(8):1567-1582.
[217]Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults:the atherosclerosis risk in communities(ARIC) study[J].Circulation,2006,114(7):630-636.
[218]Ricci F, Fedorowski A, Radico F, et al. Cardiovascular morbidity and mortality related to orthostatic hypotension:a meta-analysis of prospective observational studies[J].Euro Heart J,2015,36(25):1609-1617.
[219]Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents[J].Am J Med,2000,108(2):106-111.
[220]Arnold AC, Raj SR. Orthostatic hypotension: a practical approach to investigation and management[J].Can J Cardiol,2017,33(12):1725-1728.
[221]Ong HL, Abdin E, Seow E, et al. Prevalence and associative factors of orthostatic hypotension in older adults: results from the well-being of the Singapore elderly (WiSE) study[J].Arch Gerontol Geriatr,2017,72(24):146-152.
[222]Cyndya S, Lewis Arnold L, Italo B. ASH position paper:evaluation and treatment of orthostatic hypotension[J].J Clin Hypertens,2013,15(3):147-153.
[223]Brignole M, Moya A, de Lange FJ, et al. 2018 ESC guidelines for the diagnosis and management of syncope[J].Eur Heart J,2018,39(21):1883-1948.
[224]Chisholm P, Anpalahan M. Orthostatic hypotension: pathophysiology, assessment, treatment and the paradox of supine hypertension[J].Intern Med J,2017,47(4):370-379.
[225]Arnold AC, Okamoto LE, Alfredo G, et al. Angiotensin Ⅱ, independent of plasma renin activity, contributes to the hypertension of autonomic failure[J].Hypertension,2013,61(3):701-706.
[226]Shannon J, Jordan J, Costa F, et al. The hypertension of autonomic failure and its treatment[J].Hypertension,1997,30(5):1062-1067.
[227]Staessen JA, Gasowski J, Ji GW, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials[J].Lancet,2000,355(9207):865-872.
[228]华琦,皮林,李东宝,等.高血压病患者昼夜血压节律对心脏结构和功能的影响[J].中华心血管病杂志,2003,31(8):594-596.
[229]Hansen TW, Li Y, Boggia J, et al. Predictive role of the nighttime blood pressure[J].Hypertension,2011,57(1):3-10.
[230]Metoki H, Ohkubo TM, Asayama K, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study[J].Hypertension,2006,47(2):149-154.
[231]Paolo V, Fabio A, Giovanni M, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications[J].Hypertension,2012,60(1):34-42.
[232]Hermida RC, Ayala DE, Mojón A, et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk[J].J Am Coll Cardiol,2011,58(11):1165-1173.
[233]Park S, Jastremski CA, Wallace JP. Time of day for exercise on blood pressure reduction in dipping and nondipping hypertension[J].J Hum Hypertens,2005,19(8):597-605.
[234]Takeda A, Toda T, Fujii T, et al. Bedtime administration of long-acting antihypertensive drugs restores normal nocturnal blood pressure fall in nondippers with essential hypertension[J].Clin Exp Nephrol,2009,13(5):467-472.
[235]路岩,朱丹,郝宇,等.住院老年高血压患者伴发餐后低血压的临床观察[J].中华高血压杂志,2017,25(2):145-151.
[236]Kazushi D, Kazuyo I, Iwao S, et al. Effects of daily water drinking on orthostatic and postprandial hypotension in patients with multiple system atrophy[J].J Neurol,2007,254(6):735-740.
[237]Gentilcore D, Hausken T, Meyer JH, et al. Effects of intraduodenal glucose, fat, and protein on blood pressure, heart rate, and splanchnic blood flow in healthy older subjects[J].Am J Clin Nutr,2008,87(1):156-161.
[238]Nair S, Visvanathan R, Gentilcore D. Intermittent walking: a potential treatment for older people with postprandial hypotension[J].J Am Med Dir Assoc,2015,16(2):160-164.
[239]Oberman AS, Harada RK, Gagnon MM, et al. Effects of postprandial walking exercise on meal-related hypotension in frail elderly patients[J].Am J Cardiol,1999,84(9):1130-1132.
[240]Qiao W, Li J, Li Y, et al. Acarbose, the α-glucosidase inhibitor, attenuates the blood pressure and splanchnic blood flow responses to meal in elderly patients with postprandial hypotension concomitant with abnormal glucose metabolism[J].Blood Press Monit,2016,21(1):38-42.
[241]谢志泉,林仲秋,王银玲,等. 广州军队高龄老年高血压的特点[J].中华高血压杂志,2011,19(6):557-560.
[242]王银玲,谢志泉,邓玉,等. 中老年男性高血压患者血压晨峰临床分析[J].中华内科杂志,2011,50(12):1030-1033.
[243]孙宁玲,喜杨,荆珊,等. 左旋氨氯地平的时间药理学对纠正老年非杓型高血压的作用[J].中华高血压杂志,2007,15(1):26-29.
[244]许耀,郝云霞,崔爱东,等. 硝苯地平控释片不同时间给药对高血压患者血压变异性的影响[J].中华高血压杂志,2015,23(6):543-548.
[245]Charach G, Rabinovich PM. Seasonal changes in blood pressure and frequency of related complications in elderly israeli patients with essential hypertension[J].Gerontology,2004,50(5):315-321.
[246]苏海.血压的季节性变化[J].中华高血压杂志,2009,17(10):880-883.
[247]Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study[J].J Am Coll Cardiol,2005,46(3):508-515.
[248]Miki H, Akira M, Kei A, et al. Relationship of dysregulation of glucose metabolism with white-coat hypertension: the Ohasama study[J].Hypertens Res,2010,33(9):937-943.
[249]Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension:analysis from the Dallas heart study[J].J Am Soc Hypertens,2015,66(20):2159-2169.
[250]王磊,李南方,周克明,等. 难以控制的高血压628例病因分析[J].中华心血管病杂志,2009,37(2):138-141.
[251]上海慢性肾脏病早发现及规范化诊治与示范项目专家组.慢性肾脏病筛查诊断及防治指南[J].中国实用内科杂志,2017,37(1):28-34.
[252]Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism:case detection, diagnosis, and treatment:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab,2016,101(5):1889-1916.
[253]中华医学会内分泌学分会肾上腺学组. 原发性醛固酮增多症诊断治疗的专家共识[J].中华内分泌代谢杂志,2016,32(3):188-195.
[254]中国医疗保健国际交流促进会血管疾病高血压分会专家共识起草组. 肾动脉狭窄的诊断和处理中国专家共识[J].中国循环杂志,2017,32(9):835-844.
[255]Abela R, Ivanova S, Lidder S, et al. An analysis comparing open surgical and endovascular treatment of atherosclerotic renal artery stenosis[J].Eur J Vasc Endovasc Surg,2009,38(6):666-675.
[256]中国医师协会高血压专业委员会,中华医学会呼吸病学分会睡眠呼吸障碍学组. 阻塞性睡眠呼吸暂停相关性高血压临床诊断和治疗专家共识[J].中华高血压杂志,2012,20(12):1119-1124.
[257]Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005[J].Sleep,2005,28(4):499-521.
[258]中华医学会呼吸病学分会睡眠呼吸障碍学组.阻塞性睡眠呼吸暂停低通气综合征患者持续气道正压通气临床应用专家共识(草案)[J].中华结核和呼吸杂志,2012,35(1):13-18.
[259]王晓宇,孙丽,李悦.药源性高血压[J].中华高血压杂志,2012,20(12):1188-1190.
[260]Virdis A, Ghiadoni L, Taddei S, et al. Clinical management of drug-induced hypertension: 2013 practical recommendations of the Italian Society of Hypertension (SIIA)[J].High Blood Press Cardiovasc Prev,2014,21(1):77-79.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |